ClearPoint Neuro Q4 revenue $5.2M (+21%); FY2022 revenue $20.6M (+26%) missing guidance; FY2023 guide $25-27M

ClearPoint Neuro, Inc.

2022-FY EPS reported -$0.68 revenue$20,551,000

Preliminary Q4 2022 revenue $5.2M (+21% YoY); biologics/drug delivery $2.3M (+37%); functional neurosurgery $2.3M (+7%).
Full year 2022 revenue $20.6M (+26% YoY), below guidance of $21-22M; cash burn $3.0M in Q4; cash $37.5M at year-end.
FY2023 revenue guidance $25-27M (22-31% growth); backlog at highest level; CEO cites Q4 timing issues.
Key upcoming milestones: PTC BLA submission for Upstaza, PRISM laser system commercial launch, 10 new centers, 8 FDA submissions.
Added multiple new biologics/drug delivery partners, total >50; 11 new centers installed in 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ClearPoint Neuro, Inc. reported the fourth fiscal quarter ended December 31, 2022 results: revenue $5.2 million.

Period: the fourth fiscal quarter ended December 31, 2022
Revenue: $5.2 million
Result: preliminary results

Exact text from the filing

financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Preliminary Unaudited Financial Highlights • Preliminary unaudited revenue of $5.2 million, a 21% year-over-year increase; • Increased biologics and drug delivery revenue to $2.3 million, a 37% year-over-year increase; • Increased functional neurosurgery products and

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ClearPoint Neuro, Inc. reported full year ended December 31, 2022 results: revenue $20.6 million. Guidance initiated.

Period: full year ended December 31, 2022
Revenue: $20.6 million
Guidance: initiated
Result: preliminary results

Exact text from the filing

cash equivalents, and short-term investments at December 31, 2022. Full Year 2022 Preliminary Unaudited Financial Highlights • Achieved preliminary unaudited record revenue of $20.6 million, a 26% year-over-year increase, versus most recent guidance of $21.0 - $22.0 million; • Increased biologics and drug delivery revenue to $9.1 million, a 34% year-over-year

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-23-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.